← Eichor
Study identifier: NCT06271265 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

Condition: Postoperative Pain  ·  Sponsor: Pacira Pharmaceuticals, Inc

PhasePhase 1
Planned participants48
Who can joinAll sexes, 0 Years to 6 Years
Healthy volunteersNo

About this study

This Phase 1, multicenter, open-label, randomized, bupivacaine-controlled study is designed to evaluate the pharmacokinetics (PK) and safety of EXPAREL vs. bupivacaine HCl for postsurgical analgesia in pediatric subjects aged 0 to less than 6 years of age undergoing cardiac surgery, utilizing local infiltration analgesia (LIA).

This description comes directly from the study's public registry record.

Talk to the study team

Sarah Shaffer  ·  973-451-4071  ·  sarah.shaffer@pacira.com

Always discuss trial participation with your own doctor first.

Locations (5)

Indiana University Health, Riley Hospital For ChildrenIndianapolis, Indiana, United StatesRecruiting
St. Louis Children's Hospital (SLCH)St Louis, Missouri, United StatesRecruiting
Duke University Health SystemDurham, North Carolina, United StatesRecruiting
University of Oklahoma (OU) - Medical Center - The Children's HospitalOklahoma City, Oklahoma, United StatesRecruiting
The University of Texas Health Science Center at Houston (UTHSC-H) - McGovern Medical SchoolHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06271265